Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines.
Wang, Jiang Huai
Coffey, John Calvin
Qadri, Syed Suhail
Redmond, Henry Paul
AffiliationDepartment of Cardiothoracic Surgery, Cork University Hospital, Cork, Republic of, Ireland.
MeSHAnalysis of Variance
Carcinoma, Non-Small-Cell Lung/*enzymology
Carcinoma, Small Cell/*enzymology
Dose-Response Relationship, Drug
NF-kappa B/antagonists & inhibitors
Tumor Cells, Cultured
p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
MetadataShow full item record
CitationAnn Surg Oncol. 2007 Sep;14(9):2678-84. Epub 2007 Jun 30.
JournalAnnals of surgical oncology
AbstractBACKGROUND: Cyclooxygenase-2 enzyme (COX-2) is overexpressed in human non-small cell lung cancer (NSCLC) but is not expressed in small cell lung cancer. Selective COX-2 inhibitors have been shown to induce apoptosis in NSCLC cells, an effect which is associated with the regulation of intracellular MAP kinase (MAPK) signal pathways. Our aims were to characterize the effects of COX-2 inhibition by rofecoxib on apoptosis in human NSCLC and small cell lung cancer cell lines. METHODS: The human NSCLC cell line NCI-H2126 and small cell lung cancer cell line DMS-79 were used. Constitutive COX-2 protein levels were first determined by Western blot test. Levels of apoptosis were evaluated by using propidium iodide staining on FACScan analysis after incubation of NCI-H2126 and DMS-79 with p38 MAPK inhibitor SB202190 (25 ?microM), NF-kappaB inhibitor SN50 (75 microg/mL), and rofecoxib at 100 and 250 microM. All statistical analysis was performed by analysis of variance. RESULTS: Western blot test confirmed the presence of COX-2 enzyme in NCI-H2126 and absence in DMS-79. Interestingly, rofecoxib treatment demonstrated a dose-dependent increase in apoptosis in both cell lines. Given this finding, the effect of rofecoxib on NF-kappaB and p38 MAPK pathways was also examined. Apoptosis in both cell lines was unaltered by SN50, either alone or in combination with rofecoxib. A similar phenomenon was observed in NCI-H2126 cells treated with SB202190, either alone or in combination with rofecoxib. In contrast, p38 MAPK inhibition greatly upregulated DMS-79 apoptosis in a manner that was unaltered by the addition of rofecoxib. CONCLUSIONS: Rofecoxib led to a dose-dependent increase in apoptosis in both tumor cell lines. This effect occurred independently of COX-2, NF-kappaB, and p38 MAPK pathways in DMS-79 cells. As such, rofecoxib must act on alternative pathways to regulate apoptosis in human small cell lung cancer cells.
- Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
- Authors: Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, Wo TY, Huang YJ, Tseng SC, Lin YW
- Issue date: 2014 Apr 1
- Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
- Authors: Wang LH, Li Y, Yang SN, Wang FY, Hou Y, Cui W, Chen K, Cao Q, Wang S, Zhang TY, Wang ZZ, Xiao W, Yang JY, Wu CF
- Issue date: 2014 Jan 21
- IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2.
- Authors: Patel S, Vetale S, Teli P, Mistry R, Chiplunkar S
- Issue date: 2012 Mar
- Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells.
- Authors: Hendrickx N, Volanti C, Moens U, Seternes OM, de Witte P, Vandenheede JR, Piette J, Agostinis P
- Issue date: 2003 Dec 26
- Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells.
- Authors: Yu JA, Kalatardi S, Dohse J, Sadaria MR, Meng X, Fullerton DA, Weyant MJ
- Issue date: 2012 Sep